Lv1
2 积分 2024-01-24 加入
Odds Ratios and Risk Ratios: What’s the Difference and Why Does It Matter?
3个月前
已完结
Odds Ratios—Current Best Practice and Use
3个月前
已完结
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
3个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
4个月前
已完结
Breaking the yield–selectivity trade-off in polystyrene waste valorization via tandem depolymerization and hydrogenolysis
5个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
5个月前
已完结
Global burden of MASLD-IBD comorbidity from 1990 to 2021 and trend prediction to 2050
6个月前
已完结
Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states
6个月前
已完结
Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53‐mutant mantle cell lymphoma
6个月前
已完结
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
7个月前
已完结
皖公网安备34019202002308
